BSE · 524703
Sandu Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹17 Cr with net profit ₹0 Cr — a 0.24% net margin, versus 5.22% the period before.
Shareholding
As of 2026-06-30
- Promoter37.79%
- Public62.21%
- DII0.01%
10,268 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #34 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,844 Cr | 84.8 | 22.1 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,722 Cr | 160.16 | 9.47 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,169 Cr | 112.12 | 3.97 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,728 Cr | 100.21 | 19.19 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,444 Cr | 114.3 | 5.42 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹18,707 Cr | 65.53 | 4.79 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,893 Cr | 50.97 | 4.59 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,834 Cr | 28.32 | 3.91 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,964 Cr | 47.2 | 6.39 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,826 Cr | 141.3 | 4.04 | 8.95% | 11.15% |
| Sandu Pharmaceuticals Ltd.(this company) | ₹37 Cr | 23.85 | 1.11 | 3.69% | 2.32% |
AI analysis
AI-generated · google/gemini-2.5-flashSandu Pharmaceuticals Ltd. has a market capitalization of Rs 37 Cr. The company reported revenue of Rs 67.36 Cr and a net profit of Rs 1.5517 Cr for the year ending Mar 2025. Its earnings per share (EPS) stood at Rs 1.61, and the return on equity (ROE) was 369.3%.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Return on Equity (ROE) is high at 369.3% for the last reported period.
- +The profit margin is high at 232.2%.
Negatives
- −Revenue growth for the latest annual period is not available.
- −The dividend yield is unspecified at 210, which may indicate a data error or an unusually high figure.
- −Quarterly results are not available after Mar 2025, leading to incomplete recent performance insights.
- −Shareholding data for FIIs is 0%, indicating no foreign institutional investor participation.
Financial performance
For the financial year ending Mar 2025, Sandu Pharmaceuticals Ltd. generated a revenue of Rs 67.3599 Cr. The company's net profit for the same period was Rs 1.5517 Cr. The earnings per share (EPS) was reported at Rs 1.6.
Profitability & returns
The company's profit margin for the last reported period was 232.2%. Return on equity (ROE) for Sandu Pharmaceuticals Ltd. stood at 369.3%, while return on capital employed (ROCE) was 5.3225%. Basic EPS was Rs 1.61.
Balance sheet
Sandu Pharmaceuticals Ltd. has a book value per share of Rs 34.63. The debt-to-equity ratio is 0, indicating no debt on its books as per the provided data.
Ownership & pledges
As of June 30, 2026, promoters held 37.7865% of the company's shares. Public shareholding was 62.2083%, and DIIs held 0.0052%. There were no shares pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sandu Pharmaceuticals Ltd.share price & fundamentals